EP4045022C0 - Zusammensetzung zur verhinderung und behandlung von tauopathien - Google Patents

Zusammensetzung zur verhinderung und behandlung von tauopathien

Info

Publication number
EP4045022C0
EP4045022C0 EP20780933.6A EP20780933A EP4045022C0 EP 4045022 C0 EP4045022 C0 EP 4045022C0 EP 20780933 A EP20780933 A EP 20780933A EP 4045022 C0 EP4045022 C0 EP 4045022C0
Authority
EP
European Patent Office
Prior art keywords
tauopathies
prevention
treatment
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20780933.6A
Other languages
English (en)
French (fr)
Other versions
EP4045022A2 (de
EP4045022B1 (de
Inventor
De Fonseca Fernando Rodriguez
Galera Juan Antonio Navarro
Llano Elena Baixeras
Del Olmo Juan Manuel Decara
Vera Dina Medina
Gambero Antonio Jesús López
Perez Juan Suarez
Merino Carlos Sanjuan
Del Valle Cristina Rosell
Morón Francisco Javier Pavón
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Malaga
Servicio Andaluz de Salud
Original Assignee
Universidad de Malaga
Servicio Andaluz de Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Malaga, Servicio Andaluz de Salud filed Critical Universidad de Malaga
Priority to EP25184120.1A priority Critical patent/EP4599696A3/de
Publication of EP4045022A2 publication Critical patent/EP4045022A2/de
Application granted granted Critical
Publication of EP4045022B1 publication Critical patent/EP4045022B1/de
Publication of EP4045022C0 publication Critical patent/EP4045022C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP20780933.6A 2019-09-09 2020-09-09 Zusammensetzung zur verhinderung und behandlung von tauopathien Active EP4045022B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP25184120.1A EP4599696A3 (de) 2019-09-09 2020-09-09 Zusammensetzung und verfahren zur verbesserung oder förderung einer gesunden metabolischen alterung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382778.9A EP3789018A1 (de) 2019-09-09 2019-09-09 Zusammensetzung und verfahren zur steigerung oder förderung der sekretion von ghrelin zur förderung einer gesunden metabolischen alterung
PCT/EP2020/075180 WO2021048195A2 (en) 2019-09-09 2020-09-09 Composition and methods for enhancing or promoting a healthy metabolic aging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP25184120.1A Division EP4599696A3 (de) 2019-09-09 2020-09-09 Zusammensetzung und verfahren zur verbesserung oder förderung einer gesunden metabolischen alterung

Publications (3)

Publication Number Publication Date
EP4045022A2 EP4045022A2 (de) 2022-08-24
EP4045022B1 EP4045022B1 (de) 2025-07-09
EP4045022C0 true EP4045022C0 (de) 2025-07-09

Family

ID=67902476

Family Applications (3)

Application Number Title Priority Date Filing Date
EP19382778.9A Withdrawn EP3789018A1 (de) 2019-09-09 2019-09-09 Zusammensetzung und verfahren zur steigerung oder förderung der sekretion von ghrelin zur förderung einer gesunden metabolischen alterung
EP20780933.6A Active EP4045022B1 (de) 2019-09-09 2020-09-09 Zusammensetzung zur verhinderung und behandlung von tauopathien
EP25184120.1A Pending EP4599696A3 (de) 2019-09-09 2020-09-09 Zusammensetzung und verfahren zur verbesserung oder förderung einer gesunden metabolischen alterung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19382778.9A Withdrawn EP3789018A1 (de) 2019-09-09 2019-09-09 Zusammensetzung und verfahren zur steigerung oder förderung der sekretion von ghrelin zur förderung einer gesunden metabolischen alterung

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP25184120.1A Pending EP4599696A3 (de) 2019-09-09 2020-09-09 Zusammensetzung und verfahren zur verbesserung oder förderung einer gesunden metabolischen alterung

Country Status (8)

Country Link
US (1) US20220313620A1 (de)
EP (3) EP3789018A1 (de)
JP (2) JP2022547641A (de)
CN (2) CN120938973A (de)
CA (1) CA3153663A1 (de)
ES (1) ES3041902T3 (de)
PL (1) PL4045022T3 (de)
WO (1) WO2021048195A2 (de)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20060004096A1 (en) * 2004-05-28 2006-01-05 Joseph Larner Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
JP2008510494A (ja) * 2004-08-25 2008-04-10 マルチ・フォーミュレーションズ・リミテッド 骨格筋における異化過程の失活及びタンパク質合成のための組成物並びに方法
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
WO2008025116A1 (en) * 2006-08-31 2008-03-06 New Nitro Formulations Ltd. Composition and method for enhancing or promoting the activity of insulin, enhancing skeletal muscle growth, reducing skeletal muscle loss, and increasing the energy supply to skeletal muscle
KR100844363B1 (ko) * 2007-09-05 2008-07-07 충남대학교산학협력단 D-피니톨을 유효성분으로 포함하는 골 대사성 질환의 예방 또는 치료용 조성물
CN101612142A (zh) * 2008-06-25 2009-12-30 广州威尔曼新药开发中心有限公司 肌醇衍生物或其盐在制药中的用途
ITFI20110252A1 (it) * 2011-11-22 2013-05-23 Lo Li Pharma Srl Composizione farmaceutica comprendente myo-inositolo e d-chiro-inositolo.
CA2941650A1 (en) * 2014-03-05 2015-09-11 Humanetics Corporation Predicting and reducing cognitive decline based on gsk-3 levels
KR101671502B1 (ko) * 2015-07-13 2016-11-02 주식회사 디와이내츄럴 피니톨, d-카이로-이노시톨, 또는 이들의 유사 화합물을 유효성분으로 포함하는 여성 갱년기 증상의 개선, 예방, 또는 치료용 조성물
JP6838146B2 (ja) * 2016-10-06 2021-03-03 ディーワイ ナチュラル カンパニー リミテッド ピニトール、ｄ−カイロ−イノシトール、又はこれらの類似化合物を有効成分として含む、女性の更年期症状の改善、予防、又は治療用の組成物

Also Published As

Publication number Publication date
WO2021048195A9 (en) 2022-04-21
JP2025169353A (ja) 2025-11-12
CN120938973A (zh) 2025-11-14
JP2022547641A (ja) 2022-11-14
PL4045022T3 (pl) 2025-11-17
EP4045022A2 (de) 2022-08-24
CN114641281A (zh) 2022-06-17
CA3153663A1 (en) 2021-03-18
EP4045022B1 (de) 2025-07-09
US20220313620A1 (en) 2022-10-06
EP4599696A2 (de) 2025-08-13
WO2021048195A3 (en) 2021-04-29
EP3789018A1 (de) 2021-03-10
ES3041902T3 (en) 2025-11-17
EP4599696A3 (de) 2026-01-07
WO2021048195A2 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
EP3655534C0 (de) Zusammensetzungen und verfahren zur behandlung von beta-hämoglobinopathien
EP3784260A4 (de) Zusammensetzung zur behandlung von hautleiden
EP3603636A4 (de) Gegen s1pr4 gerichtete zusammensetzung zur prävention oder behandlung von nichtalkoholischer steatohepatitis
EP3952840A4 (de) Pharmazeutische zusammensetzungen und verfahren zur behandlung von mentalen, verhaltensbezogen, kognitiven störungen
EP3790563A4 (de) Zusammensetzung zur behandlung von hautleiden
EP4094754C0 (de) Zusammensetzungen zur behandlung und/oder prävention von proteinaggregationserkrankungen
EP3398437A4 (de) Metconazohaltige pestizidzusammensetzung zur vorbeugung und behandlung von ährenfusariosen und verwendung davon
EP3920898C0 (de) Verfahren und zusammensetzungen zur behandlung von schlafapnoe
EP3677265C0 (de) Zusammensetzung zur vorbeugung oder behandlung von schlafstörungen
EP4313010C0 (de) Verbindungen zur verwendung in der behandlung und prävention von covid-19
EP4241837C0 (de) Nicotinamid-mononukleotid-derivate zur behandlung und prävention von polycythemia vera.
EP3558335A4 (de) Caspase-1-inhibition und deren verwendung zur vorbeugung und behandlung von neurologischen erkrankungen
EP3881849C0 (de) Zusammensetzung mit aptamer als wirkstoff zur behandlung und vorbeugung von degenerativen hirnerkrankungen
EP3755319A4 (de) Verbindungen und zusammensetzungen zur behandlung von muskelkrankheiten
EP3610879A4 (de) Zusammensetzung zur behandlung und/oder vorbeugung von alzheimer-krankheit
EP3552632A4 (de) Medizinische zusammensetzung zur behandlung und prävention von chronischen erkrankungen
EP4241768A4 (de) Zusammensetzung zur behandlung von gefässerkrankungen, zusammensetzung zur prävention von gefässerkrankungen, zusammensetzung zur behandlung von bluthochdruck und zusammensetzung zur prävention von bluthochdruck
EP4073102A4 (de) Zusammensetzungen und verfahren zur prävention und behandlung von gehörverlust
EP4017496C0 (de) Formulierungen zur vorbeugung und/oder behandlung von peripherer neuropathie und deren assoziierten erkrankungen
EP3889250A4 (de) Phascolarctobacterium faecium zur verwendung bei der prävention und behandlung von fettleibigkeit und ihren komorbiditäten
EP3829553C0 (de) Zusammensetzung zur verwendung bei der vorbeugung und/oder behandlung von urogenitalmukosa
EP3870200C0 (de) Zusammensetzung zur behandlung von übergewicht und/oder adipositas
EP3814375A4 (de) Antikörper zur behandlung von synukleinopathien und nervenentzündungen
EP3758739C0 (de) Behandlung und prävention von präeklampsie
EP3651785C0 (de) Zusammensetzungen und verfahren zur behandlung von myelinerkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220406

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240916

REG Reference to a national code

Ref country code: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031050000

Ipc: A61K0031075000

Ref country code: DE

Ref legal event code: R079

Ref document number: 602020054241

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031050000

Ipc: A61K0031075000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A23L 33/125 20160101ALI20250127BHEP

Ipc: A61P 3/06 20060101ALI20250127BHEP

Ipc: A61P 19/10 20060101ALI20250127BHEP

Ipc: A61P 9/12 20060101ALI20250127BHEP

Ipc: A61P 9/10 20060101ALI20250127BHEP

Ipc: A61P 3/10 20060101ALI20250127BHEP

Ipc: A61P 5/06 20060101ALI20250127BHEP

Ipc: A61P 1/16 20060101ALI20250127BHEP

Ipc: A61P 35/00 20060101ALI20250127BHEP

Ipc: A61P 29/00 20060101ALI20250127BHEP

Ipc: A61P 25/28 20060101ALI20250127BHEP

Ipc: A61P 25/16 20060101ALI20250127BHEP

Ipc: A61P 19/02 20060101ALI20250127BHEP

Ipc: A61K 31/05 20060101ALI20250127BHEP

Ipc: A61K 31/075 20060101AFI20250127BHEP

INTG Intention to grant announced

Effective date: 20250206

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020054241

Country of ref document: DE

U01 Request for unitary effect filed

Effective date: 20250807

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250819

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251001

REG Reference to a national code

Ref country code: CH

Ref legal event code: R17

Free format text: ST27 STATUS EVENT CODE: U-0-0-R10-R17 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251007

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250926

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250924

Year of fee payment: 6

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 6

Effective date: 20250926

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 3041902

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20251117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251109

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251010

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251001

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250924

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251009

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251001

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250709